SCHEMBL2602809

SCHEMBL2602809

C[C@H](c1ccccc1)N1CCOC(c2ccccc2)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 0.54
MC4R P32245 1/20 0.49
LTA4H P09960 3/20 0.48
CCR5 P51681 1/20 0.45
OPRM1 P35372 3/20 0.43
OPRK1 P41145 2/20 0.43
OPRL1 P41146 2/20 0.43
OPRD1 P41143 1/20 0.42
HTR1A P08908 2/20 0.40
CHRM2 P08172 1/20 0.40
DRD3 P35462 1/20 0.40
HTR2B P41595 1/20 0.40
DRD4 P21917 1/20 0.40
JAK2 O60674 1/20 0.40
JAK1 P23458 1/20 0.40
MOGAT2 Q3SYC2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
CYP3A4 P08684 1/20 0.38
TSHR P16473 1/20 0.38
CYP2C19 P33261 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2605879 0.92 CYP2D6 (0.49) CYP2D6MC4RLTA4HCCR5OPRM1
SCHEMBL2115070 0.91 CYP2D6 (0.47) CYP2D6MC4RLTA4HCCR5OPRM1
SCHEMBL2115059 0.87 CYP2D6 (0.44) CYP2D6MC4RLTA4HOPRM1OPRK1
SCHEMBL2602805 0.87 CYP2D6 (0.44) CYP2D6MC4RLTA4HCCR5OPRM1
SCHEMBL537262 0.87 CYP2D6 (0.44) CYP2D6MC4RLTA4HOPRM1OPRK1
SCHEMBL2119158 0.87 LTA4H (0.49) CYP2D6MC4RLTA4HOPRM1OPRK1
SCHEMBL2116698 0.85 LTA4H (0.47) CYP2D6MC4RLTA4HOPRM1OPRK1
SCHEMBL2602808 0.84 LTA4H (0.42) CYP2D6MC4RLTA4HCCR5OPRM1
SCHEMBL2114930 0.81 DRD3 (0.42) CYP2D6LTA4HDRD3CYP3A4CYP2C19
SCHEMBL2117155 0.81 OGA (0.41) CYP2D6MC4RLTA4HCCR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9108957-B2 3-[1,4]oxazepane-4-pyrimidone derivatives MITSUBISHI TANABE PHARMA CORPORATION (JP) 2015-08-18 US disclosed
US-20120095216-A1 3-[1,4]OXAZEPANE-4-PYRIMIDONE DERIVATIVES SANOFI (FR) 2012-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095216-A1 3-[1,4]OXAZEPANE-4-PYRIMIDONE DERIVATIVES PSEN1, MAPT, PSEN2 CYP2D6 2595/4885MC4R 2572/4885LTA4H 4183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.